Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics.
Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. · 2022
Read Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. by Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9495787.txt.
Introduction
Bhalani and co-authors survey techniques that raise the bioavailability of poorly water-soluble drugs. Low solubility caps the power of many drug molecules. It skews absorption, binding, and spread through the body. About 40% of new chemical entities hit trouble at the formulation stage for this reason.
Oral forms make up more than half of all dosage forms. A drug that will not dissolve in water struggles there. The review groups fixes by approach. Particle size cuts include milling and nano sizing. Solid dispersions and solid solutions form another family. Emulsions, micelles, and microemulsions get full coverage. So do cyclodextrin complexes, drug salts, and prodrugs. Crystal engineering and solid lipid nanoparticles close the set. Each method is matched to the drug classes it suits best.
Catalog record
| CREATOR | Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 99 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics By Dixit V Bhalani, Bhingaradiya Nutan, Avinash Kumar, Arvind K Singh Chandel, Santosh Aryal, Pradeep Kumar Bolla Published in: Biomedicines DOI: 10.3390/biomedicines10092055 ABSTRACT Abstract The low water solubility of pharmacoactive molecules limits their pharmacological potential, but the solubility parameter cannot compromise, and so different approaches are employed to enhance their bioavailability. Pharmaceutically active molecules with low solubility convey a higher risk of failure for drug innovation and development. Pharmacokinetics, pharmacodynamics, and several other parameters, such as drug distribution, protein binding and absorption, are majorly affected by their solubility. Among all pharmaceutical dosage forms, oral dosage forms cover more than 50%, and the drug molecule should be water-soluble. For good therapeutic activity by the drug molecule on the target site, solubility and bioavailability are crucial factors. The pharmaceutical industry’s screening programs identified that around 40% of new chemical entities (NCEs) face various difficulties at the formulation and development stages. These pharmaceuticals demonstrate less solubility and bioavailability. Enhancement of the bioavailability and solubility of drugs is a significant challenge in the area of pharmaceutical formulations. According to the Classification of Biopharmaceutics, Class II and IV drugs (APIs) exhibit poor solubility, lower bioavailability, and less dissolution. Various technologies are discussed in this article to improve the solubility of poorly water-soluble drugs, for example, the complexation of active molecules, the utilization of emulsion formation, micelles, microemulsions, cosolvents, polymeric micelle preparation, particle size reduction technologies, pharmaceutical salts, prodrugs, the solid-state alternation technique, soft gel technology, drug nanocrystals, solid dispersion methods, crystal engineering techniques and nanomorph technology. This review mainly describes several other advanced methodologies for solubility and bioavailability enhancement, such as crystal engineering, micronization, solid dispersions, nano sizing, the use of cyclodextrins, solid lipid nanoparticles, colloidal drug delivery systems and drug conjugates, referring to a number of appropriate research reports. Keywords: solubility, bioavailability, dissolution, nanoparticles, encapsulation, BCS classification, low water solubility, solid dispersion, crystal engineering, solid lipid nanoparticles, drug conjugates, micronization, micelles 1. INTRODUCTION The solubility of the drug, the solution, and its gastrointestinal permeability are essential factors that control the amount of absorption and absorption speed, along with the bioavailability of the drug [1]. A necessary factor involved in absorption after a drug’s oral administration is the aqueous solubility of therapeutics. The drug solubility is the dissolution rate at which the drug molecule or the dosage form allows for entering the solution, and it is essential when the time of dissolution is restricted [2]. However, the drug’ bioavailability depends on water solubility, dissolution rate, drug permeability, susceptibility to efflux mechanisms, and first-pass metabolism [3]. “Solubility” has been well-defined as the quantity of solute, which dissolves in a quantity of solvent. Quantity refers as the concentration of the solute in a saturated solution at a definite temperature. The solubility has been represented through multiple concentration expressions—for example, parts, percentage, molality, molarity, volume fraction, and mole fraction. Qualitatively, solubility can be termed as a spontaneous collaboration between two substances to create a homogenous dispersion at the molecular level. The solute can be referred to as at equilibrium with the solvent in a saturated solution [4,5,6]. In recent years, according to drug detection, the number of poorly soluble drugs has increased, with 70% of novel medications presenting low aqueous solubility [7]. The controlling factors for the in vivo bioavailability of oral formulations of these drugs are the low solubility and low dissolution rate in gastrointestinal solutions. Thus, an essential issue relating to drug development has been recognized as being in vitro dissolution and increasing the speed of dissolving low solvable drugs in addition to improving their bioavailability, representing a major task for pharmaceutical experts. [8,9]. For the medicinal product to be immersed, it must exist in a water-soluble state at the place of absorption [10,11,12]. The solubility and permeability represent promising factors for in vivo absorption. They can be improved through solubility enhancement techniques [13]. Rebamipide belongs to BCS class IV drugs. It exhibits poor bioavailability and has difficulties in formulation preparation for oral administration. Due to its limitations, it is impossible to formulate a self-nano emulsifying drug delivery system (SNEDDS) formulation using this substance. To enhance the solubility of this drug, a SNEDDS formulation was prepared by complexing rebamipide with its counter ion. Tetra-butyl phosphonium hydroxide (TBPOH) and NaOH were used as counter ions to prepare a complex. Okawa et al. reported that the complexes prepared with rebamipide, Reb–TBPOH complex and Reb–NaOH complex, showed enhanced solubility and absorption in in vitro as well as in in vivo studies. Asper recent scenario of pharmaceutical developing market Figure 1 demonstrates the development of different formulations and their ratio as per BCS classification. [Figure: Solubility challenges that plague the oral drug-delivery frontier. The Biopharmaceutics Classification System (BCS) uses drug permeability and solubility as metrics for oral absorption. The four categories include BCS Class I (orange: high solubility, high permeability), Class II (blue: low solubility, high permeability), Class III (black: high solubility, low permeability), and Class IV (yellow: low solubility, low permeability). The pie charts to the right show the estimated distribution of marketed and pipeline drugs by BCS classes. The pharmaceutical company data are also presented in the pie charts. Reprinted and adapted with permission from ref. [14]. Copyright 2018 Bioconjugate chemistry.] Quercetin is a highly hydrophobic drug, which is a polyphenolic flavonoid. It finds application as an antioxidant. It exhibits anti-proliferative and chemopreventive characteristics. It was found to have potential against colon, lung, ovarian and breast cancer but, due to its poor solubility and low bioavailability, its pharmacological effects are limited. Kakran et al. used bottom-up and top-down approaches as side reduction techniques to prepare nanoparticles [15]. High-pressure homogenization and bead milling approaches were applied top-down and EPN-evaporative precipitation of nanosuspension was applied as a bottom-up technique to prepare quercetin nanoparticles with enhanced solubility and bioavailability. Ting et al. drew special attention to specialized polymer design strategies and commercial products, which can enhance the solubility of extremely hydrophobic drugs, and can minimize the probability of drug recrystallization. The specially prepared excipients are molecularly customized polymers which can restructure the APIs into potential oral medication [14]. United States Pharmacopeia (USP) has already approved several such specialized polymers as an excipient for the preparation of solid oral formulations. Natural derivatives and some synthetically prepared polymers were frequently used to enhance the bioavailability of amorphous drugs. At present, several amorphous drugs are available on the market, as listed in Table 1. Hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone), PEG (Polyethylene glycol), HPMCAS (hydroxypropyl methylcellulose acetate succinate (PVP), polyvinylpyrrolidone vinyl acetate (PVP-VA) and several other specialized polymers were approved as excipient by FDA. These were used with drugs such as verapamil (Product trade name: ISOPTIN-SRE, excipient: HPC/HPMC by Abbott Laboratories), Nilvadipine (product trade name: Nivadil, excipient: HPMC by Fujisawa Pharmaceuticals, Tokyo, Japan ), tacrolimus (product trade name: PROGRAF, excipient: HPMC by Astellas Pharma US Inc., Northbrook, IL, USA), nabilone (product trade name: Cesamet, excipient: PVP by Valeant Pharmaceuticals, Bridgewater, NJ, USA ), griseofulvin (product trade name: GRIS-PEG, excipient: PEG by Pedinol Pharmacal Inc. & Novartis, Bridgewater, NJ, USA ), ritonavir (product trade name: NORVIR, excipient: PVA-VA by AbbVie Inc., Chicago, IL, USA) and telaprevir (product trade name: INCIVEK, excipient: HPMCAS by Vertex